145 related articles for article (PubMed ID: 27746632)
1. Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas).
Lyu SM; Wu JY; Byun JY; Choi HY; Park SH; Choi YW
Ann Dermatol; 2016 Oct; 28(5):548-554. PubMed ID: 27746632
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide 3-kinase is not overexpressed in melanocytic lesions.
Singh RS; Diwan AH; Zhang PS; Prieto VG
J Cutan Pathol; 2007 Mar; 34(3):220-5. PubMed ID: 17302605
[TBL] [Abstract][Full Text] [Related]
3. Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression.
Sung WW; Chang CH
Tzu Chi Med J; 2022; 34(1):1-7. PubMed ID: 35233349
[TBL] [Abstract][Full Text] [Related]
4. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
6. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of p53 is a late event in the development of malignant melanoma.
Lassam NJ; From L; Kahn HJ
Cancer Res; 1993 May; 53(10 Suppl):2235-8. PubMed ID: 8485708
[TBL] [Abstract][Full Text] [Related]
8. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma.
Tsao H; Mihm MC; Sheehan C
J Am Acad Dermatol; 2003 Nov; 49(5):865-72. PubMed ID: 14576666
[TBL] [Abstract][Full Text] [Related]
9. Acral melanocytic neoplasms: a histologic analysis of 158 lesions.
Boyd AS; Rapini RP
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):740-5. PubMed ID: 7929919
[TBL] [Abstract][Full Text] [Related]
10. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
Slipicevic A; Holm R; Nguyen MT; Bøhler PJ; Davidson B; Flørenes VA
Am J Clin Pathol; 2005 Oct; 124(4):528-36. PubMed ID: 16146807
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
[TBL] [Abstract][Full Text] [Related]
12. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
14. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Khalifeh I; Taraif S; Reed JA; Lazar AF; Diwan AH; Prieto VG
Am J Surg Pathol; 2007 Jul; 31(7):1130-6. PubMed ID: 17592281
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
16. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
17. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
18. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
[TBL] [Abstract][Full Text] [Related]
19. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
20. Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy.
Altamura D; Altobelli E; Micantonio T; Piccolo D; Fargnoli MC; Peris K
Arch Dermatol; 2006 Sep; 142(9):1123-8. PubMed ID: 16982999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]